CTVA Form 4: Robert King Exercises Options, Sells Shares at $74.20 Avg
Rhea-AI Filing Summary
Robert D. King, EVP, Crop Protection Business at Corteva, reported multiple equity transactions on 08/29/2025. He exercised 14,960 non-qualified options with an exercise price of $58.67 and 9,337 options at $62.29, receiving the same number of common shares. On the same date he sold 37,280 shares at a weighted average price of $74.1951, with sale prices ranging $74.17–$74.23. Following these transactions his reported beneficial ownership is 49,262.2876 shares (direct). The filing notes inclusion of 25.3808 shares from dividend reinvestment and provides option vesting/expiration details for the reported grants.
Positive
- Clear disclosure of option exercises and sales including exercise prices, share counts, and weighted average sale price
- Footnotes explain the weighted average sale price range and dividend reinvestment inclusion
- Vesting and expiration dates provided for the reported option grants
Negative
- None.
Insights
TL;DR: Insider exercised options and sold shares in a same-day transaction mix, a routine liquidity and compensation event.
The Form 4 shows contemporaneous option exercises and a substantial sale by an executive. The exercises at $58.67 and $62.29 converted options into common shares before a delegated sale of 37,280 shares at a weighted average of $74.1951, reducing reported direct holdings to 49,262.2876 shares. The filing discloses a small dividend reinvestment of 25.3808 shares and standard vesting/expiration schedules. These actions are common for executives to realize option value and diversify; the filing does not indicate any unusual trading program or Rule 10b5-1 plan.
TL;DR: Transactions reflect executive compensation realization with disclosed vesting and expiration terms; governance disclosure appears complete.
The Form 4 identifies the reporting person and relationship to the issuer and provides required footnotes clarifying the weighted average sale price range, dividend reinvestment, and vesting chronology. Option details include exercise prices, number of options, expiration dates, and post-transaction derivative holdings. The signature by power-of-attorney is included. No regulatory exceptions or omissions are noted within the form's content.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right-to-buy) | 14,960 | $0.00 | -- |
| Exercise | Non-Qualified Stock Option (right-to-buy) | 9,337 | $0.00 | -- |
| Exercise | Common Stock | 14,960 | $58.67 | $878K |
| Exercise | Common Stock | 9,337 | $62.29 | $582K |
| Sale | Common Stock | 37,280 | $74.1951 | $2.77M |
Footnotes (1)
- The price reported represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $74.17 to $74.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Includes acquisition of 25.3808 shares pursuant to dividend reinvestment. The options became fully exercisable on April 4, 2025, the third anniversary of the grant date. One-third of the options became exercisable on February 28, 2024, an additional one-third of the options became exercisable on February 28, 2025, and the remaining one-third of the options will become exercisable on February 28, 2026, the third anniversary of the grant date.
